← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2003Last known activity
Nov 4, 2024
Timeline
1940s
- Jun 1, 1948
National Health Service, United Kingdom— Founded
Drugs by trial phase (42 distinct, 21 trials)
Phase 4 (5 own, 0 via acquisition)
Phase 3 (15 own, 0 via acquisition)
Phase 2 (16 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Asthma
- Blood Coagulation Disorders
- Carcinoma, Squamous Cell
- Communicable Diseases
- Diarrhea
- Dyspnea
- Fatty Liver
- Glioblastoma
- Hemostatic Disorders
- Hypertension
- Infections
- Influenza, Human
- Kidney Diseases
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Melanoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Non-alcoholic Fatty Liver Disease
- Obesity
- Prostatic Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Respiratory Tract Infections
Recent trials (25)
- NCT06630260OfficialPhase 1/Phase 2Nov 4, 2024
- NCT06632236OfficialPhase 1Oct 9, 2024
- NCT06126731Overall official - principal investigatorPhase 1/Phase 2Nov 2, 2023
- NCT05671562Overall official - principal investigatorN/AMay 3, 2023
- NCT05671562OfficialN/AMay 3, 2023
- NCT04458311Study directorPhase 1/Phase 2Dec 1, 2020
- NCT04419610Overall official - principal investigatorEarly Phase 1Jul 31, 2020
- NCT03673787Overall official - principal investigatorPhase 1/Phase 2Aug 13, 2018
- NCT03177187Overall official - principal investigatorPhase 1/Phase 2Jun 1, 2017
- NCT03281941Lead sponsorN/AAug 6, 2016
- NCT03281941Reponsible party - principal investigatorN/AAug 6, 2016
- NCT02424851Overall official - principal investigatorPhase 2Nov 1, 2014
- NCT01997112CollaboratorPhase 4Jan 1, 2014
- NCT01985750CollaboratorEarly Phase 1Nov 1, 2013
- NCT01355575CollaboratorPhase 4May 1, 2011
Details
- Founded
- London, GB Jun 1, 1948
- Last known activity
- Nov 4, 2024